Accuray Incorporated
Healthcare sector | Medical Devices industry
Metrics for ARAY
| Price | $0.4 |
|---|---|
| Shares Outstanding | 118.78M |
| All-Time Low | $0.50 |
| 52-Week Low | $0.50 |
Balance Statement Metrics
| Net Cash / Share | $0 |
|---|---|
| Net Current Assets / Share | $-0.86 |
| Net Tangible Assets / Share | $0 |
| Shares Outstanding Ave Change (Annual) | 6.41% |
| Shares Δ YoY | 12.42% |
| Avg CA Burn (Annual %) | -3.28% (as of 3-1-2026) |
| Avg CA Burn (Quarterly %) | -2.63% (as of 3-1-2026) |
Earning Metrics
| Max Earning Power / Share | $-0.27 |
|---|---|
| Adjusted Earning Power |
$-1.1
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
| Non-Cash Charges to Market Cap |
4.34%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
| Avg EBITDA (5Y) | 11.5M (as of 3-1-2026) |
| Avg EBITDA (5Q) | 3.8M (as of 3-1-2026) |
| Avg Net Income (5Y) | -7.9M (as of 3-1-2026) |
| Avg Net Income (5Q) | -6.6M (as of 3-1-2026) |
Indicators
| Dividend indicators | Value | Date |
|---|---|---|
| Current Dividend Streak | No | 3-1-2026 |
| Consecutive Years Paid | No | 3-1-2026 |
| Pays Dividend | No | 3-1-2026 |
| Income indicators | Value | Date |
|---|---|---|
| EBITDA Positive | No | 3-1-2026 |
| Net Income Positive | No | 3-1-2026 |
| Current Dividend Streak | No | 3-1-2026 |
Metric History Explorer
Pick a metric to view its history table and chart.
Tangible Book Value Per Share History
Formula: Tangible Book Value / shares from balance statements. Includes 6 quarterly + 4 annual.
Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).
| Report Date | Period | TBV / Share | Tangible Book Value | Shares Used |
|---|---|---|---|---|
| 2025-12-31 | Quarterly | $-0.04 | -4.4M ($-4,430,000) | 118.8M (118,786,404) |
| 2025-09-30 | Quarterly | $0.04 | 4M ($4,043,000) | 113.3M (113,281,068) |
| 2025-06-30 | Quarterly | $0.21 | 23.4M ($23,352,000) | 112.6M (112,643,852) |
| 2025-06-30 | Annual | $0.21 | 23.4M ($23,352,000) | 112.6M (112,643,852) |
| 2025-03-31 | Quarterly | $-0.08 | -8.2M ($-8,163,000) | 102.9M (102,850,591) |
| 2024-12-31 | Quarterly | $-0.10 | -9.8M ($-9,789,000) | 102.8M (102,808,518) |
| 2024-09-30 | Quarterly | $-0.13 | -12.6M ($-12,635,000) | 100.4M (100,435,251) |
| 2024-06-30 | Annual | $-0.13 | -12.6M ($-12,647,000) | 100.2M (100,194,932) |
| 2023-06-30 | Annual | $-0.04 | -4.2M ($-4,232,000) | 96.5M (96,534,609) |
| 2022-06-30 | Annual | $-0.05 | -4.9M ($-4,901,000) | 93.5M (93,499,500) |
Revenue History (Annual)
Revenue from income statements. Includes 4 annual.
Chart plots one annual Revenue point per report date.
| Report Date | Revenue |
|---|---|
| 2025-06-30 | 458.5M ($458,505,000) |
| 2024-06-30 | 446.6M ($446,551,000) |
| 2023-06-30 | 447.6M ($447,605,000) |
| 2022-06-30 | 429.9M ($429,909,000) |
Dividend Payments
Historical cash dividends per share from Yahoo ex-dividend dates.
| Date | Dividend / Share |
|---|---|
| No dividend payment history available yet | |
Shares Outstanding Changes
| Date | Shares Outstanding | Delta |
|---|---|---|
| 2026-02-24 | 118,782,630 | +5,441,498 |
Short Interest Changes
Latest short-interest change: 6,598,752 shares (6.38% of float) | Days to cover: 5.09
| Date | Short Interest | Delta | Δ % |
|---|---|---|---|
| 2026-03-24 | 6,598,752 shares | +1,127,636 | +20.61% |
| 2026-03-12 | 5,471,116 shares | -218,339 | -3.84% |
| 2026-02-27 | 5,689,455 shares | +859,991 | +17.81% |
| 2026-02-11 | 4,829,464 shares | +694,430 | +16.79% |
Interesting Volume Days
Volume/ratio use shares outstanding as of the event date (frozen).
| Date | Volume | Shares Outstanding | Volume / Shares | Price |
|---|---|---|---|---|
| No interesting volume events | ||||
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.